Correction to: Comparative effectiveness of netupitant-palonosetron plus dexamethasone versus aprepitant-based regimens in mitigating chemotherapy-induced nausea and vomiting: a meta-analysis of randomized controlled trials. [PDF]
Oncologisteuropepmc +1 more source
Effect of Neurokinin-1 Receptor Antagonists on Experimental Postoperative Adhesion: A Systematic Review and Meta-Analysis with Trial Sequential Analysis of Preclinical Studies. [PDF]
Medicina (Kaunas)Hwang HJ +4 more
europepmc +1 more source
Cannabinoid Hyperemesis Syndrome Treated With Fosaprepitant: A Case Report. [PDF]
CureusMoore MD, Alzghari SK, Soliman AN.
europepmc +1 more source
Comparative effectiveness of netupitant-palonosetron plus dexamethasone versus aprepitant-based regimens in mitigating chemotherapy-induced nausea and vomiting: a meta-analysis of randomized controlled trials. [PDF]
OncologistLuo WT, Chang CL, Huang TW, Gautama MSN.
europepmc +1 more source
Neoadjuvant chemo-immunotherapy in a kidney transplant recipient with locally advanced non-small cell lung cancer: a case report of a therapeutic dilemma. [PDF]
Transl Lung Cancer ResRogier J +7 more
europepmc +1 more source
Exploring antiemetic strategies in hematologic malignancies: a comprehensive literature review and evaluation of antiemetic efficacy in patients receiving high-dose chemotherapy prior to hematopoietic stem cell transplantation. [PDF]
Support Care CancerJordan K, Jordan B, Burgt JV, Jahn F.
europepmc +1 more source
Fosaprepitant for the prevention of multiple-day cisplatin chemotherapy-induced nausea and vomiting: a prospective randomized controlled study. [PDF]
BMC Pharmacol ToxicolWang L +8 more
europepmc +1 more source
[Aprepitant and pruritus--comment].
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2013 openaire +1 more source
Related searches:
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +1 more source
Comparisons of aprepitant and ondansetron
American Journal of Health-System Pharmacy, 2007We are responding to the letter from Cavaretta and Noviasky[1][1] concerning Merck’s two Phase III studies of aprepitant 40 mg p.o. versus ondansetron 4 mg (as the hydrochloride salt) i.v. in the prevention of postoperative nausea and vomiting (PONV).[2][2],[3][3] Prophylactic ondansetron ...
Alexandra, Carides +4 more
openaire +2 more sources